Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership

[ad_1] All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only…

J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion

[ad_1] An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson…

Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization

[ad_1] Angus Smith joins as Chief Financial Officer Wing-Yen Wong, M.D., joins as interim Chief Medical Officer CAMBRIDGE, Mass., January 04, 2024–(BUSINESS WIRE)–Be Biopharma, Inc. (“Be Bio”), a company pioneering…

Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15

[ad_1] An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing Rights Dec 4…

Opinion: Big Tech’s Move into Biopharma Could Disrupt the Industry | BioSpace

[ad_1] Pictured: Abstract 3D grid/iStock, carloscastilla Artificial intelligence is a rapidly evolving field that has experienced exponential growth over the past decade. During that time, the accumulation of vast amounts…

Biopharma Layoff Tracker 2023: Atsena, uniQure, Kezar and More Cut Staff | BioSpace

[ad_1] 2022 saw myriad ups and downs in terms of the economy, and as it ebbed and flowed, so too did the job market. This trend has continued throughout 2023.…

Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies

[ad_1] INDIANAPOLIS, Oct. 3, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with…

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

[ad_1] 2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20%2 year-over-year due to portfolio prioritization and organizational efficiencies…

CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment

[ad_1] CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing…

The role of AI on the biopharma HR strategy and decision making

[ad_1] By Ganesh Nikam From Common to Crucial, AI is advancing rapidly, covering the entire spectrum of complexity of business activities and tasks. Each passing day, AI technology, applications, case…